Immunology

The professor of rheumatology and immunology created an early computer database to follow rheumatology patients. The knowledge he gained from it precipitated his “compression of morbidity” hypothesis.

The Moderna and Pfizer BioNTech vaccines prevented COVID-19 infection in cancer patients, particularly in those whose treatment concluded more than six months before vaccination, say researchers at Stanford, Harvard and the VA.

New medications help many people with inflammatory conditions and may ease severe COVID-19, but they carry risks.

Stanford researchers have developed a synthetic, tumor-targeting molecule that promotes immune activation and tumor regression in laboratory mice after it’s injected into their bloodstreams.

A potential COVID-19 vaccine, delivered via a squirt up the nose, shows promise in mice.

In large study of dialysis patients, low immune response to the COVID-19 vaccine made by Johnson & Johnson indicates that a booster shot might be needed.

In a study of mRNA-based COVID-19 vaccine doses given at Stanford Medicine, vaccine allergies were rare, mild and mostly triggered by a vaccine additive, not the mRNA.

A study spearheaded by Stanford researchers indicates that at least 1 in 5 hospitalized COVID-19 patients develops new antibodies that attack their own tissue within a week of admission.

Scientists at Stanford and the Buck Institute have found a way to predict an individual’s immunological decline as well as the likelihood of incurring age-associated diseases and becoming frail.

In COVID-19 patients whose symptoms were mild, Stanford researchers found that they were more likely than sicker patients to have signs of prior infection by similar, less virulent coronaviruses.

An infusion of monoclonal antibodies can ease COVID-19 symptoms and reduce complications in recently diagnosed, non-hospitalized people at high risk. Now people can refer themselves.